The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries

Trial Profile

The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 13 May 2016 Status changed from not yet recruiting to recruiting.
    • 25 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top